Drug Profile
VIB 9600
Alternative Names: FcγRIIA antibody - AstraZeneca; MEDI9600; VIB9600Latest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer Horizon Therapeutics plc
- Class Immunotherapies; Monoclonal antibodies
- Mechanism of Action Fc gamma receptor IIA antagonists; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (IV, Infusion)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (SC, Injection)
- 15 Mar 2021 Viela Bio has been acquired and merged into Horizon Therapeutics plc